LIVE POLIO IRUS VACCINES

More documents

Recommendations

Info

ITnTTITTTIIrmrTTTmTTmTmm - niiii iiiiuiiiiiiiiirrrmiiiirmii iimim SIXTH SESSION WEDNESDAY, 8 JUNE 1950, 2:00 P.M. Chairman DR. PIERRE R. LÉPINE Chief, Virus Research Division Institut Pasteur Paris, France TOPIC III. EFFICACY. (A) LABORATORY EVIDENCE (continuation) (1) ANTIBODY RESPONSE (c) Influence of Dosage and Regimen Presentation of Papers by: Dr. Henry Bauer Dr. Juan Embil, Jr. (DISCUSSION) (2) INTERFERENCE BY HETEROTYPIC POLIOVIRUSES OR BY OTHER VIRUSES Presentation of Papers by: Dr. Albert B. Sabin Dr. Manuel Ramos Alvarez (DISCUSSION) TOPIC III. EFFICACY. (B) FIELD EVIDENCE Presentation of Paper by: Dr. Marina K. Voroshilova for Dr. Mikhail P. Chumakov (DISCUSSION) 355
Page 1 and 2:
LIVE POLIO IRUS VACCINES Papers Pre
Page 3 and 4:
SECOND INTERNATIONAL CONFERENCE ON
Page 5:
Preface The accumulation of informa
Page 8 and 9:
Page Discussion .......... .......
Page 10 and 11:
Page 6. Vaccination of Full-Term In
Page 12 and 13:
Page 23. Vaccination against Poliom
Page 14 and 15:
Dr. Ghislain COURTOIS Director, Pri
Page 16 and 17:
Dr. Edith PETTE Institute for the R
Page 18:
imimmmmmñimmimmm-ñmñmñrmimmimmm
Page 21 and 22:
4 Introductory Remarks 4 Introducto
Page 23 and 24:
6 General Considerations immunity a
Page 25 and 26:
8 General Considerations from accep
Page 27 and 28:
10 General Considerations 10 Genera
Page 29 and 30:
_nTlmmlllllTlllllllnT/I1T~lllmlimll
Page 31 and 32:
14 Safety-Laboratory Evidence of At
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
- 26 Safety-Laboratory Evidence of
Page 45 and 46:
DISCUSSION CHAIRMAN ANDERSON: There
Page 47 and 48:
30 Discussion CHAIRMAN ANDERSON: Th
Page 49 and 50:
32 TABLE 1. Safety-Laboratory Evide
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
40 Discussion Of the 22 monkeys inf
Page 59 and 60:
Page 61 and 62:
DISCUSSION CHAIRMAN ANDERSON: Thank
Page 63 and 64:
46 Discussion a paralytic case. Thi
Page 65 and 66:
48 Discussion + - + + I + - I + + 1
Page 67 and 68:
50 Discussion sages of neurovirulen
Page 70 and 71:
UUYaYLlrmUIIIIIIYYIi1IYllllliTI11II
Page 72 and 73:
Application of Genetic Markers to D
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Discussion 67 TABLE 1. INCIDENCE OF
Page 86 and 87:
Experimental Studies on Animals wit
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
6. DETECTION OF A "NON-DETECTABLE"
Page 98 and 99:
Detection of a "Non-Detectable" Sim
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Discussion 87 Dr. Koprowski's state
Page 106 and 107:
Discussion 89 recognize its effects
Page 108 and 109:
Laboratory Investigations of Attenu
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Discussion 99 In the case of Table
Page 118 and 119:
8. BEHAVIOR OF COLD MUTANTS OF POLI
Page 120 and 121:
Behavior of Cold Mutants of Poliovi
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
DISCUSSION CHAIRMAN BURNET: Thank y
Page 128:
IULUUmmiillaYIIiiiiIllnllTrTnTnTm T
Page 131 and 132:
114 Safety-Field Evidence of Safety
Page 133 and 134:
Page 135 and 136:
118 S afety-Field Evidence of S af
Page 137 and 138:
Page 139 and 140:
122 Discussion 122 Discussion~~~~~~
Page 141 and 142:
10. LABORATORY INVESTIGATIONS OF TH
Page 143 and 144:
126 VIRUS 1 MAhONEY Safety-Field Ev
Page 145 and 146:
128 Safety-Field Evidence óf Safet
Page 147 and 148:
Page 149 and 150:
DISCUSSION CHAIRMAN ZHDANOV: This p
Page 151 and 152:
11. EPIDEMIOLOGICAL AND VIROLOGICAL
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
12. SPREAD OF A VACCINE STRAIN OF P
Page 163 and 164:
Page 165 and 166:
148 Saf ety-Field Evidence of Saf e
Page 167 and 168:
Page 169 and 170:
152 Saf ety-Field Evidence of Safet
Page 171 and 172:
Page 173 and 174:
DISCUSSION CHAIRMAN ZHDANOV: The pa
Page 175 and 176:
158 Discussion 158 Díscussion~~~~~
Page 177 and 178:
160 Discussion specimens. We were u
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
. . . 168 Safety-Field Evidence of
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
14. THE CAPACITY OF LIVE ATTENUATED
Page 193 and 194:
176 Saf ety-Field Evidence of Saf e
Page 195 and 196:
... ____ v __ _"_ _. ___.__ __ .,_.
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 204 and 205:
"""lliiiiirmlilrrmiiiiiiiii iiiii,,
Page 206 and 207:
Field, Laboratory Experiences With
Page 208 and 209:
16. STUDIES ON LIVE POLIOVIRUS VACC
Page 210 and 211:
Studies on Live Poliovirus Vaccine
Page 212 and 213:
; _ o - -01 1 0 h 4.cccM oe u, Co F
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Da. HORSTMANN: If I may answer for
Page 222 and 223:
Discussion 205 Discussion 205 tried
Page 224 and 225:
NOTE: The Spanish translation of th
Page 226 and 227:
Vaccination of Pregnant Women and Y
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Development and Persistence of Poli
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Virologic, Serologic Investigations
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
_ _ _ _ _ _ _ _ Virologic, Serologi
Page 282 and 283:
Page 284 and 285:
cARE NUC:4I Discussion 267 CUAw # J
Page 286 and 287:
Discussion 269 in the investigation
Page 288 and 289:
Virological Findings, Antibody Resp
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
4. ROUTINE IMMUNIZATION WITH ATTENU
Page 296 and 297:
Routine Immunization With Attenuate
Page 298 and 299:
Page 300:
Page 304 and 305:
mmrriiiiiiiiiiiinniiiiiiiriiimmmmmn
Page 306 and 307:
Experimental Infectionwith CHATAtte
Page 308 and 309:
Experimental Infection with CHATAtt
Page 310 and 311:
Experimental Infection with CHATAtt
Page 312 and 313:
Vaccination of Full-Term Infants wi
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321: Response of Newborn Infants to Vacc
Page 326 and 327: Susceptibility of Newborn Infants t
Page 332 and 333: 9. IMMUNIZATION OF NEWBORN INFANTS
Page 334 and 335: Immunization of Newborn Infants wit
Page 340 and 341: Discussion 323 vaccinated siblings
Page 342 and 343: Discussion 325 Discussion 325 ance
Page 344 and 345: transplacental antibodies, or antib
Page 346 and 347: Discussion 329 Discussion 329 born
Page 348 and 349: Recent Experience with Lederle Triv
Page 358 and 359: 11. FURTHER EXPERIENCES WITH ORAL P
Page 360 and 361: Further Experiences with Oral Polio
Page 370: Further Experiences with Oral Polio
Page 375 and 376: 358 Efficacy-Laboratory Evidence TA
Page 385 and 386: 368 Efflcacy-Laboratory Evídence 3
Page 387 and 388: 370 Efficacy-Laboratory Evidence RE
Page 389 and 390: 372 372 Discussion Discussion~~~~~~
Page 391 and 392: 374 Discussion 374 Discussion~~~~~
Page 393 and 394: 376 Discussion 376 Discussion~~~~~~
Page 395 and 396: 378 Efficacy-Laboratory Evidence 10
Page 397 and 398: 380 Efficacy-Laboratory Evidence 10
Page 401 and 402: 384 Effieacy-Laboratory Evidence 38
Page 403 and 404: 15. USE OF SABIN'S LIVE POLIOVIRUS
Page 405 and 406: 388 Efficacy-Laboratory Evidence o
Page 409 and 410: _ 392 Efficacy-Laboratory Evidence
Page 419 and 420: 402 Efficacy-Laboratory Evidence z
Page 421 and 422:
404 Efficacy-Laboratory Evidence )
Page 423 and 424:
406 Efficacy-Laboratory Evidence c
Page 425 and 426:
408 Efficacy-Laboratory Evidence l)
Page 427 and 428:
DISCUSSION CHAIRMAN LÉPINE: The pa
Page 429 and 430:
412 Discussion tion. I do not see h
Page 431 and 432:
414 Efficacy-Field Evidence ference
Page 433 and 434:
416 Effcacy-Field Evidence TABLE 3.
Page 435 and 436:
418 Efficacy-Field Evidence DAYS OF
Page 437 and 438:
preparation. Large-scale field tria
Page 439 and 440:
422 Efficacy-Field Evidence taneous
Page 441 and 442:
424 Efficacy-Field Evidence TABLE 1
Page 443 and 444:
426 Efficacy-Field Evidence 2048 ,a
Page 445 and 446:
428 Efficacy-Field Evidence 60o S0
Page 447 and 448:
430 Discussion 430 Discussion~~~~~~
Page 449 and 450:
432 Discussion tioned already in th
Page 452 and 453:
lilllmlllllll'll1lllllilrrmllllllll
Page 454 and 455:
Large-Scale Field Trial with Oral C
Page 456 and 457:
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
18. PRELIMINARY REPORT OF EPIDEMIOL
Page 464 and 465:
Epidemiological Surveillance in Mas
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
DISCUSSION CHAIRMAN RHODES: These t
Page 476 and 477:
Discussion 459 -~~~~Dsuso 5 We did
Page 478 and 479:
Discussion 461 logical anomalies of
Page 480 and 481:
Discussion 463 The majority of chil
Page 482:
case of poliomyelitis, if it was po
Page 485 and 486:
Page 487 and 488:
470 Efficacy-Field Evidence 470 Eff
Page 489 and 490:
Page 491 and 492:
20. LIVE VIRUS VACCINE STUDIES IN S
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
DISCUSSION CHAIRMAN RHODES: These t
Page 499 and 500:
21. MATERIAL ON THE IMMUNOLOGICAL A
Page 501 and 502:
484 Efficacy-Field Evidence 484 Efi
Page 503 and 504:
486 Efficacy-Field Evidence 486 iEf
Page 505 and 506:
488 Efficacy-Field Evidence - TABLE
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
494 Efficaey-Field Evidence TABLE 9
Page 513 and 514:
496 Efficaey-Field Evidence TABLE 1
Page 515 and 516:
498 Efficacy-Field Evidence Qo - Co
Page 517 and 518:
500 Etfficacy-Field Evidence 500 Ef
Page 520:
lmllliiimlll1llrrmmIiiiiiiiiiiiiii,
Page 523 and 524:
506 Discussi on hausted the morbidi
Page 525 and 526:
Page 527 and 528:
510 Efficacy-Field Evidence b 'r3 `
Page 529 and 530:
512 ol o c,- 4 3- 0 7 Efficacy-Fiel
Page 531 and 532:
514 Efficacy-Field Evidence b, U *
Page 533 and 534:
516 Efficacy-Field Evidence o e 0 1
Page 535 and 536:
518 Efficacy-Field Evidence in the
Page 537 and 538:
520 Efficacy-Field Evidence thing w
Page 539 and 540:
23. VACCINATION AGAINST POLIOMYELIT
Page 541 and 542:
Page 543 and 544:
Page 545 and 546:
528 Efficacy-Field Evidence MAP 2.
Page 547 and 548:
Page 549 and 550:
DISCUSSION CHAIRMAN STUART-HARRIS:
Page 551 and 552:
534 Efficacy-Field Evidence a still
Page 553 and 554:
536 Efficacy-Field Evidence frigera
Page 555 and 556:
538 TABLE 3. Efficacy-Field Evidenc
Page 557 and 558:
540 Efficacy-Field Evidence sented
Page 559 and 560:
Page 561 and 562:
544 Efficacy-Field Evidence Antibod
Page 563 and 564:
546 Efficacy-Field Evidence 250t 20
Page 565 and 566:
Page 567 and 568:
550 Efficacy-Field Evidence FIGURE
Page 569 and 570:
552 Efficacy-Field Evidence u o o
Page 571 and 572:
-Y 554 Efficacy-Field Evidence TABL
Page 573 and 574:
556 -- Efficacy-Field Evidence 0
Page 575 and 576:
c 558 Efficacy-Field Evidence o z o
Page 577 and 578:
560 Efficacy-Field Evidence Clayton
Page 579 and 580:
562 Efficacy-Field Evidence 2. Triv
Page 581 and 582:
564 Efficacy-Field Evidence and by
Page 583 and 584:
566 Efficacy-Field Evidence establi
Page 585 and 586:
568 Efficacy-Field Evidence Costa R
Page 587 and 588:
570 Efficacy-Fi eld Evidence Two su
Page 589 and 590:
572 Efficacy-Field Evidence o0 u p
Page 591 and 592:
DISCUSSION CHAIRMAN STUART-HARRIS:
Page 593 and 594:
27. LARGE-SCALE PRACTICAL TRIALS AN
Page 595 and 596:
578 Efficacy-Field Evidence some of
Page 597 and 598:
580 Efficacy-Field Evidence vaccine
Page 599 and 600:
582 Efficacy-Field Evidence more th
Page 601 and 602:
584 Efficacy-Field Evidence medical
Page 603 and 604:
586 Efficacy-Field Evidence immuniz
Page 605 and 606:
588 Efficacy-Field Evidence nationa
Page 608 and 609:
DISCUSSION CHAIRMAN VARGAS-MÉNDEZ:
Page 610 and 611:
Discussion 593 -~~~~~isuso 9 a stoo
Page 612 and 613:
Discussion 595 If the chain of tran
Page 614 and 615:
dence of immunization within a few
Page 616 and 617:
Discussion 599 the people in a few
Page 618 and 619:
Summary of the Conference 601 prese
Page 620:
The occurrence of poliomyelitis in
Page 624 and 625:
INDEX Abad Gómez, Héctor, 369 Abo
Page 626 and 627:
Index 609 Attack rates-continued hi
Page 628 and 629:
Index 611 Chromatography purificati
Page 630 and 631:
Index 613 Dosage-continued statisti
Page 632 and 633:
Index 615 Field trials-continued Le
Page 634 and 635:
Index 617 Human tissue-culture syst
Page 636 and 637:
Index 619 Intestinal tract-continue
Page 638 and 639:
Index 621 Markush, R. E., paper 435
Page 640 and 641:
Index 623 Newborns-continued degree
Page 642 and 643:
Index 625 Poliomyelitis, paralytic-
Page 644 and 645:
Index 627 Reversion dangers of, 485
Page 646 and 647:
Index 629 Spread-continued in the c
Page 648 and 649:
Index 631 Vaccination-continued rep
Page 650 and 651:
Index 633 Vaccine, Attenuated, Triv
show all

LIVE POLIO IRUS VACCINES

Create successful ePaper yourself

Delete template?

Save as template?